My Patient Rights can help guide you in resolving issues so you can get the health care you deserve.
For years, Medicare beneficiaries living with obesity have faced a difficult reality: effective GLP-1 medications such as Wegovy and Zepbound were often financially out of reach, with monthly costs exceeding $1,000. Although costs have gone down generally, beginning July 1st many Medicare beneficiaries will have coverage through a new federal initiative known as the Medicare GLP-1 Bridge Program.
The program, announced by the Centers for Medicare & Medicaid Services (CMS), is designed to provide eligible Medicare beneficiaries access to certain FDA-approved weight management medications for a fixed cost of $50 per month. The initiative represents one of the most significant expansions of obesity treatment access for Medicare beneficiaries in decades.
What Is the Medicare GLP-1 Bridge Program?
The Medicare GLP-1 Bridge Program is a temporary demonstration project created by CMS to expand access to anti-obesity medications for Medicare beneficiaries. The program will operate outside of the traditional Medicare Part D benefit structure and is intended to provide affordable access while CMS gathers data on utilization and outcomes.
The demonstration is currently scheduled to run through December 31, 2027.
Under the program, eligible beneficiaries will pay a flat $50 copayment for a 30-day supply of covered GLP-1 medications.
Who Is Eligible?
To qualify for the Medicare GLP-1 Bridge Program, individuals must:
It’s important to note that beneficiaries who already receive GLP-1 medications through Medicare Part D for conditions such as type 2 diabetes, cardiovascular disease, obstructive sleep apnea, or other covered indications generally would not qualify for the Bridge Program because those medications are already covered under existing Medicare benefits.
Which Medications Are Covered?
The Medicare GLP-1 Bridge Program currently includes several FDA-approved medications used for chronic weight management, including:
CMS may provide additional guidance regarding participating products as the program evolves.
How Do Beneficiaries Access the Program?
Unlike some government programs, beneficiaries do not need to register or enroll separately.
To access treatment:
CMS has indicated that prior authorization requests will be submitted electronically or by fax through a centralized processing system.
Who Could Benefit?
Obesity affects millions of Americans and is associated with numerous chronic health conditions, including:
For beneficiaries who are older, have a disability or a disease, obesity can contribute to worsening health outcomes and increased healthcare costs. By lowering financial barriers to treatment, the Medicare GLP-1 Bridge Program may help beneficiaries access evidence-based therapies that support long-term weight management and improve overall health.
The program may be particularly beneficial for individuals who have previously been unable to afford GLP-1 medications despite medical recommendations from their healthcare providers.
Important Considerations
The Bridge Program is temporary. Because it is scheduled to end on December 31, 2027, patients and providers should stay informed about future Medicare coverage decisions and any policy changes that may follow.
A Significant Step Forward for Obesity Care
The launch of the Medicare GLP-1 Bridge Program signals a growing recognition that obesity is a chronic disease requiring evidence-based treatment. For eligible Medicare beneficiaries, the program offers a new opportunity to access proven medications at a cost that is far more affordable than current market prices.
My Patient Rights can help guide you in resolving issues so you can get the health care you deserve.
Find answers to commonly asked questions.
State and federal law protects your rights. When you sign up for a health plan and/or if you have problems accessing care through your health plan, it is important to know your rights.